拉米夫定治疗HBeAg阳性及阴性慢性乙型肝炎患者复发率的比较

探讨HBeAg阳性及阴性慢乙肝患者拉米夫定治疗中复发率及其影响因素。选择服用拉米夫定一年以 上的100例(其中,HBeAg阳性69例,HBeAg阴性31例)慢乙肝患者,检测复发率并分析了影响复发率的有关因素。 结果显示当服用拉米夫定12个月时HBeAg阴性及阳性群复发率分别为0％和12％,当74个月时分别为7％和 39％,两者之间有显著性差异(P<0．01) 另外,复发率仅与HBeAg存在与否有关(P<0．05),而与年龄、性别、治疗 前ALT、治疗前HBV DNA值无关。说明拉米夫定对HBeAg阴性慢乙肝远期效果比HBeAg阳性慢乙肝为好,HBeAg 存在与否影响其复发率。

The relapse rate in HBeAg- positive and HBeAg- negative chronic hepatitis B patients receiving lamivudine therapy

To evaluate the relapse rate and influencing factors after lamivudine therapy in patients with HBeAg - negative and HBeAg- positive chronic liver disease. One hundred patients with HBeAg- negative (31 cases) and HBeAg- positive (69 eases) chronic liver disease who have received lamivudine for at least one year were detected. The relapse rate were 0% and 12% in patients with HBeAg - negative and HBeAg - positive chronic liver disease who have received laniivudine 12 months. after 24 months the rate were up to 7% an 39% , there was significantly differenet in both groups ( P < 0.01). The only significant factor related with the relapse rate was HBeAg existence, however age, sex, levels of ALT and HBVDNA were not related with the relapse rate. Our results showed that long - term effect after lamivudme therapy in HBeAg - negative group was better than HBeAg positive group, HBeAg existence influenced the relapse rate.